(RTTNews) - Praxis Precision Medicines Inc. (PRAX) said that phase 2/3 Aria Study, which evaluated the efficacy and safety of PRAX-114 for monotherapy treatment of major depressive disorder (MDD), did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback